NRG
MRNA icon

Nemes Rush Group’s Moderna MRNA Stock Holding History

Nemes Rush Group’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-7,745
Closed -$825K – 767
2024
Q3 		$825K Sell
7,745
-1,427
-16% -$131K 0.12% 96
2024
Q2 		$1.09M Buy
9,172
+1,427
+18% +$181K 0.15% 83
2024
Q1 		$825K Buy
7,745
+2,308
+42% +$233K 0.12% 97
2023
Q4 		$541K Sell
5,437
-3,385
-38% -$285K 0.09% 117
2023
Q3 		$911K Buy
8,822
+3,398
+63% +$379K 0.17% 91
2023
Q2 		$659K Buy
+5,424
New +$724K 0.12% 106

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Nemes Rush Group's MRNA Position: Q4 2024 in Review

Nemes Rush Group sold out of Moderna (MRNA) in Q4 2024, closing a stake of 7,745 shares — an estimated $825K sold.

Nemes Rush Group first reported a position in MRNA in Q2 2023 and held it in 6 quarters. The position peaked at $1.09M in Q2 2024. 745 funds tracked by Wall St. Rank hold MRNA as of Q4 2024.

  • Nemes Rush Group reported no remaining Moderna position as of Q4 2024 after selling out during the quarter.
  • Nemes Rush Group sold 7,745 Moderna shares in Q4 2024, an estimated $825K.
  • Nemes Rush Group first reported a position in Moderna in Q2 2023 and held it in 6 quarters.
  • Nemes Rush Group's Moderna position peaked at $1.09M in Q2 2024.
  • 745 funds tracked by Wall St. Rank held Moderna as of Q4 2024.

Based on Nemes Rush Group's 13F filing for Q4 2024, filed 12 Feb 2025.